In the News
Congratulations to Bruce Blazar, M.D.
, Transplant Biology and Therapy Program member, on his election to membership in the Institute of Medicine at its recent annual meeting. This is one of the highest honors in the medical field, given to individuals who have demonstrated outstanding professional accomplishments and commitment to service.
In a study published in the August 12th edition of the New England Journal of Medicine, the Pediatric BMT team of Dr. John Wagner, Director, and Dr. Jakub Tolar, reported the amazing results from their first BMT clinical trial to treat Epidermolysis Bullosa (EB), a rare, genetic skin disease.
Director of the Division of Pediatric Hematology-Oncology and Blood and Marrow Transplantation Dr. John E. Wagner
is quoted in the Oncology Times, commenting on a recent article he published on the use of umbilical cord blood for transplantation: "Based on the fact that leukemia-free survival rates are similar with HLA mismatched UCB, we no longer have to think of UCB as a second-line source [of stem cells]." Click here to read the full article
New research by Dr. Michael Verneris
shows that transfusion of two rather than one unit of partially HLA-matched umbilical cord blood (UCB) appears to reduce the risk of relapse in leukemia patients in first or second complete remission.
University of Minnesota Amplatz Children's Hospital cited by U.S. News & World Report
Study findings may offer hope to more leukemia patients that they may live cancer-free.